Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
for PSMA PET-Positive Castration-Resistant Prostate Cancer
9 locations incl. San Diego
Sponsor: Convergent Therapeutics
Sex: Male·Age: 18+
Code: NCT06549465·Phase 2·Recruiting